Literature DB >> 9341197

Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.

Y Takagi1, A Pause, R C Conaway, J W Conaway.   

Abstract

Elongin C is a 112-amino acid protein that is found in mammalian cells as a positive regulatory subunit of heterotrimeric RNA polymerase II elongation factor Elongin (SIII) and as a component of a multiprotein complex containing the von Hippel-Lindau (VHL) tumor suppressor protein. As a subunit of the Elongin complex, Elongin C interacts directly with the transcriptionally active Elongin A subunit and potently induces its elongation activity; in addition, Elongin C interacts with the ubiquitin-like Elongin B subunit, which regulates the interaction of Elongin C with Elongin A. As a component of the VHL complex, Elongin C interacts directly with both Elongin B and the VHL protein. Binding of the VHL protein to Elongin C was found to prevent Elongin C from interacting with and activating Elongin A in vitro, leading to the proposal that one function of the VHL protein may be to regulate RNA polymerase II elongation by negatively regulating the Elongin complex. In this report, we identify Elongin C sequences required for its interaction with the VHL protein. We previously demonstrated that the ability of Elongin C to bind and activate Elongin A is sensitive to mutations in the C-terminal half of Elongin C, as well as to mutations in an N-terminal Elongin C region needed for formation of the Elongin BC complex. Here we show that interaction of Elongin C with the VHL tumor suppressor protein depends strongly on sequences in the C terminus of Elongin C but is independent of the N-terminal Elongin C region required for binding to Elongin B and for binding and activation of Elongin A. Taken together, our results are consistent with the proposal that the VHL protein negatively regulates Elongin C activation of the Elongin complex by sterically blocking the interaction of C-terminal Elongin C sequences with Elongin A. In addition, our finding that only a subset of Elongin C sequences required for its interaction with Elongin A are critical for binding to VHL may offer the opportunity to develop reagents that selectively interfere with Elongin and VHL function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9341197     DOI: 10.1074/jbc.272.43.27444

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein.

Authors:  A Pause; B Peterson; G Schaffar; R Stearman; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53.

Authors:  Paola Blanchette; Chi Ying Cheng; Qin Yan; Gary Ketner; David A Ornelles; Thomas Dobner; Ronald C Conaway; Joan Weliky Conaway; Philip E Branton
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

3.  The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families.

Authors:  T Kamura; S Sato; D Haque; L Liu; W G Kaelin; R C Conaway; J W Conaway
Journal:  Genes Dev       Date:  1998-12-15       Impact factor: 11.361

4.  The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity.

Authors:  J Lisztwan; G Imbert; C Wirbelauer; M Gstaiger; W Krek
Journal:  Genes Dev       Date:  1999-07-15       Impact factor: 11.361

5.  Integrated molecular analysis of clear-cell renal cell carcinoma.

Authors:  Yusuke Sato; Tetsuichi Yoshizato; Yuichi Shiraishi; Shigekatsu Maekawa; Yusuke Okuno; Takumi Kamura; Teppei Shimamura; Aiko Sato-Otsubo; Genta Nagae; Hiromichi Suzuki; Yasunobu Nagata; Kenichi Yoshida; Ayana Kon; Yutaka Suzuki; Kenichi Chiba; Hiroko Tanaka; Atsushi Niida; Akihiro Fujimoto; Tatsuhiko Tsunoda; Teppei Morikawa; Daichi Maeda; Haruki Kume; Sumio Sugano; Masashi Fukayama; Hiroyuki Aburatani; Masashi Sanada; Satoru Miyano; Yukio Homma; Seishi Ogawa
Journal:  Nat Genet       Date:  2013-06-24       Impact factor: 38.330

6.  Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists.

Authors:  Darwin L Lim; Raymond Ko; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

7.  Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.

Authors:  Renzo G DiNatale; Alexander N Gorelick; Vladimir Makarov; Kyle A Blum; Andrew W Silagy; Benjamin Freeman; Diego Chowell; Julian Marcon; Roy Mano; Alex Sanchez; Kyrollis Attalla; Stanley Weng; Martin Voss; Robert J Motzer; Paul Russo; Jonathan A Coleman; Victor E Reuter; Ying-Bei Chen; Timothy A Chan; Ed Reznik; Satish K Tickoo; A Ari Hakimi
Journal:  Eur Urol Focus       Date:  2019-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.